AstraZeneca: positive results in chronic kidney disease
(CercleFinance.com) - AstraZeneca said on Monday that its diabetes drug Farxiga reduces the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease.
In a phase III trial, Farxiga, on top of standard of care, reduced the composite measure of worsening of renal function or risk of cardiovascular or renal death by 39% compared to placebo in patients with chronic kidney disease (stages 2-4) and elevated urinary albumin excretion, the drugmaker said.
The co-chairs of the trial, two professors from the University College London,and University Medical Center Groningen, cited "impressive" results.
"These data have the potential to transform the standard of care for this patient population, which has a significant unmet need for new and improved treatment options," they said.
Chronic kidney disease affects nearly 700 million people worldwide, AstraZeneca said, with many of them are still undiagnosed, and its most common causes are diabetes and hypertension.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
In a phase III trial, Farxiga, on top of standard of care, reduced the composite measure of worsening of renal function or risk of cardiovascular or renal death by 39% compared to placebo in patients with chronic kidney disease (stages 2-4) and elevated urinary albumin excretion, the drugmaker said.
The co-chairs of the trial, two professors from the University College London,and University Medical Center Groningen, cited "impressive" results.
"These data have the potential to transform the standard of care for this patient population, which has a significant unmet need for new and improved treatment options," they said.
Chronic kidney disease affects nearly 700 million people worldwide, AstraZeneca said, with many of them are still undiagnosed, and its most common causes are diabetes and hypertension.
Copyright (c) 2020 CercleFinance.com. All rights reserved.